Davunetide: Peptide Therapeutic in Neurological Disorders
Iddo Magen and Illana Gozes
Affiliation: Lily and Avraham Gildor Chair for the Investigation of Growth Factors; Director, The Adams Super Center for Brain Studies and The Edersheim Levie-Gitter fMRI Institute; Head, the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino
acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in the laboratory of
Prof. Illana Gozes. The effects of NAP and its related peptides in models of neurodegenerative diseases and other neurological
disorders will be described here in details. Possible mechanisms of NAP actions include anti-inflammatory effect,
antioxidant activity, inhibition of protein aggregation and interaction with microtubules. In line with the fact that all of
these features are characteristic to most neurological/neurodegenerative disorders, NAP was found to have beneficial effects
on the behavioral manifestations associated with these disorders.
Keywords: Activity-dependent neuroprotective protein (ADNP), Alzheimer's disease, Davunetide, NAP, neurodegenerative
diseases, neurological disorders.
Rights & PermissionsPrintExport